News

News

WIB_icon

Can a Selinexor Combination STOMP Out Relapsed/Refractory Multiple Myeloma?

The combination of selinexor plus low-dose bortezomib and dexamethasone produced high response rates in patients with relapsed or refractory multiple myeloma (MM), with a...
WIB_icon

Duvelisib Bests Ofatumumab in Relapsed and Refractory CLL/SLL

In the phase III DUO trial, treatment with the oral phosphoinositide 3-kinase (PI3K) dual inhibitor duvelisib improved progression-free survival (PFS) and overall response, compared...

Restrictive Transfusion Therapy Safe for Cardiac Surgery Patients

Setting higher hemoglobin (Hb) thresholds for red-cell transfusion therapy in patients undergoing cardiac surgery with a moderate to high risk of death was noninferior...

Weighing Conditioning Regimens for Patients With CML Undergoing Transplant

Conditioning with a reduced-intensity, nonmyeloablative regimen was associated with similar post-transplant survival but a lower risk of chronic graft-versus-host disease (cGVHD), compared with a...

Remembering Brian P. Sorrentino, NIH Awards Washington University Leukemia Program, and more

Remembering Brian P. Sorrentino (1958-2018) Brian P. Sorrentino, MD, a gene-therapy researcher specializing in the treatment of blood and immune cell disorders, passed away...

CMS Finalizes Physician Fee Schedule for 2019

The Centers for Medicare and Medicaid Services (CMS) released its final changes to the Medicare Physician Fee Schedule and the Quality Payment Program for...

ASH Recognizes Choosing Wisely Champions, Scholar Award Winners, and more

Recognizing Champions of Waste Reduction ASH recognized three Choosing Wisely® Champions during the 2018 annual meeting in San Diego. Choosing Wisely, an initiative of the American...

FDA Approves Elotuzumab-Based Triplet Regimen for Myeloma

The FDA approved the combination of elotuzumab plus pomalidomide and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (MM)...

FDA Issues Draft Guidance on MRD in Clinical Trials

To make drug development and evaluation more efficient, the U.S. Food and Drug Administration (FDA) issued draft guidance on the use of minimal residual...

FDA Expands Brentuximab Vedotin’s Indication

Brentuximab vedotin has been approved in combination with chemotherapy for the firstline treatment of adult patients with certain peripheral T-cell lymphomas (PTCLs). The FDA granted...
Advertisement

Current Issue

January 2019 Annual Meeting Edition

This issue features highlights from the 2018 ASH Annual Meeting, including big data initiatives to improve prognosis in myelodysplastic syndromes, and more.